TY - JOUR
T1 - Safety and immunogenicity of GMZ2 - a MSP3-GLURP fusion protein malaria vaccine candidate
AU - Esen, Meral
AU - Kremsner, Peter G
AU - Schleucher, Regina
AU - Gässler, Michael
AU - Imoukhuede, Egeruan Babatunde
AU - Imbault, Nathalie
AU - Leroy, Odile
AU - Jepsen, Søren
AU - Knudsen, Birgitte Walther
AU - Schumm, Michael
AU - Knobloch, Jürgen
AU - Theisen, Michael
AU - Mordmüller, Benjamin
N1 - Keywords: Adult; Antibodies, Protozoan; Antigens, Protozoan; B-Lymphocytes; Female; Follow-Up Studies; Humans; Immunization, Secondary; Immunologic Memory; Malaria Vaccines; Malaria, Falciparum; Male; Middle Aged; Protozoan Proteins; Recombinant Fusion Proteins; Young Adult
PY - 2009
Y1 - 2009
N2 - Malaria is a major public health problem in Sub-Saharan Africa. In highly endemic regions infants, children and pregnant women are mostly affected. An effective malaria vaccine would complement existing malaria control strategies because it can be integrated in existing immunization programs easily. Here we present the results of the first phase Ia clinical trial of GMZ2 adjuvanted in aluminium hydroxide. GMZ2 is a malaria vaccine candidate, designed upon the rationale to induce immune responses against asexual blood stages of Plasmodium falciparum similar to those encountered in semi-immune individuals. Ten, 30 and 100 microg of GMZ2 were well tolerated in 30 healthy malaria-naïve German volunteers when given three times in monthly intervals. Antigen-specific antibodies as well as memory B-cells were induced and detectable throughout the one year follow-up of the study. We conclude that GMZ2 is a safe and immunogenic malaria vaccine candidate suitable for further clinical development.
AB - Malaria is a major public health problem in Sub-Saharan Africa. In highly endemic regions infants, children and pregnant women are mostly affected. An effective malaria vaccine would complement existing malaria control strategies because it can be integrated in existing immunization programs easily. Here we present the results of the first phase Ia clinical trial of GMZ2 adjuvanted in aluminium hydroxide. GMZ2 is a malaria vaccine candidate, designed upon the rationale to induce immune responses against asexual blood stages of Plasmodium falciparum similar to those encountered in semi-immune individuals. Ten, 30 and 100 microg of GMZ2 were well tolerated in 30 healthy malaria-naïve German volunteers when given three times in monthly intervals. Antigen-specific antibodies as well as memory B-cells were induced and detectable throughout the one year follow-up of the study. We conclude that GMZ2 is a safe and immunogenic malaria vaccine candidate suitable for further clinical development.
U2 - 10.1016/j.vaccine.2009.09.011
DO - 10.1016/j.vaccine.2009.09.011
M3 - Journal article
C2 - 19755144
SN - 0264-410X
VL - 27
SP - 6862
EP - 6868
JO - Vaccine
JF - Vaccine
IS - 49
ER -
